Izumi T, Yoshida M, Kamaro T, Sato H
Gan To Kagaku Ryoho. 1986 Oct;13(11):3215-20.
SF-SP which contains sustained release granules of tegafur has been reported to be effective for gastrointestinal and breast cancer. HB-AC, which is an anti-leukemic agent, is known to have considerable activity against a variety of transplanted solid tumors in rats and mice. A comparative clinical study was therefore conducted by randomized controlled trial on the two different chemotherapies, involving as SF-SP group and as SF-SP plus BH-AC group. Among 58 patients, 42 were evaluable for response (SF-SP: 20/30, SF-SP plus BH-AC: 22/28). The partial response rate of SF-SP was 15.0% (3/20) and that of SF-SP plus BH-AC was 13.6% (3/22). The toxicity rates of SF-SP and SF-SP plus BH-AC were 33.3% (10/30) and 36.0% (9/25), respectively. These results indicated that the two therapies were similar in both response and toxicity rates. However, the response appeared faster in the case of SF-SP plus BH-AC therapy than in that of SF-SP therapy.
据报道，含有替加氟缓释颗粒的SF-SP对胃肠道癌和乳腺癌有效。HB-AC是一种抗白血病药物，已知对大鼠和小鼠的多种移植实体瘤具有相当的活性。因此，通过随机对照试验对两种不同的化疗方法进行了比较临床研究，分为SF-SP组和SF-SP加BH-AC组。58例患者中，42例可评估反应（SF-SP组：20/30，SF-SP加BH-AC组：22/28）。SF-SP的部分缓解率为15.0%（3/20），SF-SP加BH-AC的部分缓解率为13.6%（3/22）。SF-SP和SF-SP加BH-AC的毒性率分别为33.3%（10/30）和36.0%（9/25）。这些结果表明，两种疗法在反应率和毒性率方面相似。然而，SF-SP加BH-AC疗法的反应似乎比SF-SP疗法更快。
